Study of serum adenosine deaminase activity and c-reactive protein in patients of rheumatoid arthritis

2020 ◽  
Vol 11 (4) ◽  
pp. 7990-7993
Author(s):  
Sangeetha R ◽  
Ramesh Raju K A P ◽  
Hemapriya S ◽  
Suganthi V ◽  
Panneerselvam P
Keyword(s):  
Rheumatoid Arthritis ◽  
Adenosine Deaminase ◽  
Treatment Plan ◽  
Colorimetric Method ◽  
Disease Score ◽  
C Reactive Protein ◽  
Positive Correlation ◽  
Reactive Protein ◽  
Adenosine Deaminase Activity

Rheumatoid arthritis (RA) is a chronic disease that causes inflammatory synovitis. The treatment plan of RA includes reducing inflammation and improving the quality of life. Hence, understanding the role of Adenosine deaminase (ADA) and C-reactive protein helps for a better plan of treatment. The present study was undertaken to determine the serum ADA activity and CRP in RA patients and correlate with the severity of the progression of the disease. 25 patients diagnosed with RA as per 2010 ACR/EULAR criteria and 25 age and sex matched healthy controls were included in the study after informed consent. Blood samples were collected from all the subjects after an overnight fast, serum separated was analyzed immediately for Adenosine deaminase(ADA) activity measured using colorimetric method of Guisti and Galanti. Disease score, C-reactive protein, RA factor, ADA and ESR were significantly higher in cases when compared with controls. Significant positive correlation was present between the disease score and C-reactive protein, RA factor among cases. A positive correlation was observed between the disease score and ADA, but it was not statistically significant among cases.

Adenosine Deaminase Activity and HLA-DRB as Diagnostic Markers for Rheumatoid Arthritis

2018 ◽  
Vol 15 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Shirin Valadbeigi ◽  
Reza Saghiri ◽  
Mina Ebrahimi-Rad ◽  
Shohreh Khatami ◽  
Hadi Akhbari
Keyword(s):  
Rheumatoid Arthritis ◽  
Adenosine Deaminase ◽  
Healthy Subjects ◽  
Hla Typing ◽  
Control Group ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Bonferroni Adjustment ◽  
Adenosine Deaminase Activity ◽  
Systemic Disorder

Background:Rheumatoid Arthritis (RA) is a chronic multi systemic disorder with the unclarified ethiopathology. Although several markers have been presented for recognition of RA, but none of them has been specific. New markers such as HLA typing and activity of Adenosine Deaminase (ADA) isoenzymes could be useful and specific.Objective:The aim of this study is to evaluate the pattern of ADA isoenzymes activity and HLA typing in both RA patients and healthy cases.Methods:Blood samples were collected from 55 RA patients and 60 healthy subjects, over a period of 6 months. Levels of C-reactive Protein (CRP), Rheumatoid Factor (RF) and ADA (ADA1, ADA2, total ADA) were measured using AVITEX kit and HITACHI Auto Analyzer. In addition, HLA-DRB1*01,*04 and *10 was detected using PCR-SSP.Results:ADA activity, particularly ADA2 level, was significantly higher among RA group (Pv <0.05). The concentrations of tADA in patients with RF and CRP positive were significantly higher (Pv <0.05). The allele prevalence of DRB1*01 was significantly higher in RA patients (13.1%) compared with control group (5.5%, respectively) (P <0.05, Bonferroni adjustment P<0.003). Calculated sensitivity and specificity for diagnostic tests in this study are listed as: CRP (75%), RF (80%), ADA (84%) and RF (90%), ADA (83%), CRP (72%), respectively.Conclusion:Increased tADA level and the frequency of DRB1*10 and *01 caused susceptibility to RA.

Role of high sensitivity C - Reactive protein and some of heavy metals in patients with rheumatoid arthritis

2020 ◽  
Vol 23 (16) ◽  
Author(s):  
Nashwan S. Albabawaty ◽  
Ali Y. Majid ◽  
Mohammed H. Alosami ◽  
Halla G. Mahmood
Keyword(s):  
Rheumatoid Arthritis ◽  
Heavy Metals ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis

2019 ◽  
Vol 91 (5) ◽  
pp. 26-33
Author(s):  
A S Avdeeva ◽  
M V Cherkasova ◽  
D A Kusevich ◽  
V V Rybakova ◽  
A S Artyuhov ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Total Dose ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
Disease Duration ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Laboratory Biomarkers

Aim: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. Materials and methods. 20 patients (pts) with rheumatoid arthritis (RA) (18 woman, mean age 61.5(54-66.5) years, mean disease duration 39.5(20-84) months, mean DAS28 5.6(4.9-6.8)) received two intravenous RTM biosimilar infusions (600 mg №2) in combination with DMARDs and glucocorticoids. Laboratory biomarkers were assessed at baseline and weeks 12 and 24 after the first infusion of RTX. Results. RTM biosimilar induced decreases in DAS28, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) at week 12 and 24, p

Alpha 1 Antitrypsin, C Reactive Protein, and Hemolysis Markers: Association With Cytokines Profile In Sickle Cell Disease Patients In Steady-State and Crisis-State

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4701-4701
Author(s):  
Magda Carvalho ◽  
Wendell Vilas Boas ◽  
Bruno Antônio Veloso Cerqueira ◽  
Joao Oliveira Reis ◽  
Theo Araujo ◽  
...  
Keyword(s):  
Steady State ◽  
Sickle Cell Disease ◽  
Significant Positive Correlation ◽  
Clinical Manifestations ◽  
Cell Disease ◽  
C Reactive Protein ◽  
Positive Correlation ◽  
Reactive Protein ◽  
Alpha 1 Antitrypsin

Introduction Sickle cell disease (SCD) has a heterogeneous clinical picture, characterized by hemolysis, chronic inflammation and vaso-occlusive events and painful crisis. Aims Investigate the levels of Alpha 1 antitrypsin (A1AT), C reactive protein (CRP), hemolysis markers and its association with cytokines profile in SCD patients in steady-state and crisis-state. Methods It was developed a cross sectional study in a total of 72 SCD patients in steady-state (SP) and 23 SCD patients in crisis (CP) age-and-sex-matched. Hematological analysis was performed by automatic cell counter, hemoglobin profile by HPLC, and biochemistry analyses of inflammation and infection markers and lipid, hepatic, and kidney metabolism markers were investigated by immunochemistry assays. Plasma levels of TNFα, IFNγ, IL-10, IL-1β, IL-6 and IL-8 were measured using Cytometric Bead Array - CBA (BD Biosciences Pharmingen, USA) according to the manufacturer’s protocol. Results Statistical analysis showed that SCD steady-state patients group had the highest IL-12 concentration (p<0.0001) and there were a decrease in TNFα, IL-10, IL-1β, and IL-6 levels (p< 0.0001) when compared to CP group (figure 1). However, significant differences in IL-8 levels were not finding in the comparison between SCD in steady-state and crisis patients groups. Biomarkers analyses of SCD steady-state patients showed significant negative correlation between IL-8 with A1AT (r= -0.25; p= 0.03) and CRP (r= -0.24; p= 0.04) and significant positive correlation with lactate dehydrogenase (LDH) (r= 0.25; p= 0.03). The IL-6 showed significant positive correlation with white blood cell count (WBC) (r= 0.52; p< 0.0001), ferritin (r= 0.30; p= 0.001) and CRP (r= 0.42; p= 0.0002). TNFα showed a significant positive correlation with leukocyte count (r= 0.28; p= 0.02) and A1AT (r= 0.29; p= 0.01) and IL-10 showed a significant positive correlation with platelets count (r= 0.30; p= 0.01) and A1AT (r= 0.29; p= 0.01). Conclusions Immunological aspects of SCD patients have been increasingly studied. The high levels of Th2 cytokines (IL-6 and IL-10) and proinflammatory cytokines (TNFα and IL-1β) in SCD patients in crisis-state, possibly is related to severe clinical manifestations, despite the fundamental role of these cytokines in the pathophysiology is not yet completely clear. The correlation between these cytokines and biomarkers associated with important clinical manifestations in SCD, such as WBC, platelet count, A1AT and CRP, highlights the important role of inflammatory mediators in SCD and its possible association with an expression or activation of adhesion molecules in neutrophils and vascular endothelium. Disclosures: No relevant conflicts of interest to declare.

SAT0046 Role of C-Reactive Protein in Osteoclastogenesis in Rheumatoid Arthritis

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 664.3-665
Author(s):  
H.-R. Kim ◽  
S.-H. Lee ◽  
S.-H. Lee ◽  
H.-Y. Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Morphofunctional properties of platelets in patients with rheumatoid arthritis

2021 ◽  
pp. 55-61
Author(s):  
Z. V. Zubkova ◽  
I. A. Novikova
Keyword(s):  
Rheumatoid Arthritis ◽  
Platelet Count ◽  
Disease Activity ◽  
Peripheral Blood ◽  
Maximum Degree ◽  
Inflammatory Process ◽  
C Reactive Protein ◽  
Platelet Activity ◽  
Reactive Protein

Objective: to assess the morphofunctional properties of platelets in patients with rheumatoid arthritis (RA) in combination with other clinical and laboratory characteristics of the disease.Materials and methods. The parameters of platelet hemostasis were studied in 51 RA patients with varying degrees of disease activity according to the DAS28 index.Results. It has been found that the count of platelets in the peripheral blood and their aggregation properties depend on the indicators of the activity of the inflammatory process (degree of activity, ESR, level of C-reactive protein). Platelet indices (MPV, P-LCR, PDW) are interrelated with the relative counts of lymphocytes and segmented neutrophils in the peripheral blood. In RA patients who are seropositive for rheumatoid factor, its titer is associated with the morphofunctional properties of platelets (platelet count, MPV, maximum degree of aggregation in the ADP test).Conclusion. The role of platelets in the RA pathogenesis is not limited exclusively to the hemostatic function. The associations we identified between the platelet activity and the clinical and laboratory characteristics of the disease are indicative of their active participation in immunological processes.

scholarly journals Inflammatory response in rheumatoid arthritis

2004 ◽  
Vol 23 (4) ◽  
pp. 375-380 ◽  
Author(s):  
Ljiljana Petrovic-Rackov ◽  
Nada Pejnovic ◽  
Zoran Mijuskovic ◽  
Gordana Ercegovic
Keyword(s):  
Rheumatoid Arthritis ◽  
Synovial Fluid ◽  
Inflammatory Response ◽  
Tnf Alpha ◽  
C Reactive Protein ◽  
General Activity ◽  
Reactive Protein ◽  
High Degree ◽  
Active Disease

The aim of the research is to determine the clinical significance of cytokines TNF-alpha, IL-12, IL-15 and IL-18 in evaluation of the activity of rheumatoid arthritis (RA). By comparing the concentrations in 30 patients with high, 14 patients with moderate and 20 patients with mild activity of RA it is established that the patients with high degree of disease activity, have significantly high (p<0.01; p<0.05) concentrations of examined cytokines and rheumatoid factor in blood and synovial fluid as well as C-reactive protein in serum in relation to patients with moderate and mild active disease. We have concluded that the cytokines concentrations can be good indicators of the degree of the general activity of RA. This research can contribute to interpretation of insufficiently well known views of pathogenesis role of cytokines in active disease.

scholarly journals The role of 14-3-3 η as a biomarker in rheumatoid arthritis

2021 ◽  
Vol 2 (2) ◽  
pp. 87-90
Author(s):  
Dima Abdelhafiz ◽  
Sally Kilborn ◽  
Marwan Bukhari
Keyword(s):  
Rheumatoid Arthritis ◽  
Response To Treatment ◽  
Inflammatory Disorder ◽  
C Reactive Protein ◽  
Prognostic Information ◽  
Reactive Protein ◽  
Appropriate Treatment ◽  
Good Disease Control ◽  
Novel Biomarkers

Abstract Rheumatoid arthritis (RA) is a chronic multisystem inflammatory disorder with significant morbidity and mortality. Making an early diagnosis and providing appropriate treatment decisions based on clinical and other parameter results in good disease control. Biomarkers, such as C reactive protein (CRP), anti-cyclic citrullinated peptides (anti-CCP), and erythrocyte sedimentation rate (ESR), have been traditionally used. Recently novel biomarkers are described. This article reviews the evidence behind a novel biomarker 14-3-3 η that has been found to provide additional diagnostic and prognostic information as well as predicting response to treatment. A systematic literature review is presented showing the evidence behind this molecule.

scholarly journals ADENOSINE DEAMINASE ACTIVITY AND SERUM C-REACTIVE PROTEIN AS PROGNOSTIC MARKERS OF CHAGAS DISEASE SEVERITY

2015 ◽  
Vol 57 (5) ◽  
pp. 385-392 ◽  
Author(s):  
Iván Darío BRAVO-TOBAR ◽  
Carlota NELLO-PÉREZ ◽  
Alí FERNÁNDEZ ◽  
Nora MOGOLLÓN ◽  
Mary Carmen PÉREZ ◽  
...  
Keyword(s):  
Adenosine Deaminase ◽  
Disease Severity ◽  
Chagas Disease ◽  
Prognostic Markers ◽  
Public Health Problem ◽  
Phase Iii ◽  
Diagnostic Tools ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Adenosine Deaminase Activity

SUMMARY Chagas disease is a public health problem worldwide. The availability of diagnostic tools to predict the development of chronic Chagas cardiomyopathy is crucial to reduce morbidity and mortality. Here we analyze the prognostic value of adenosine deaminase serum activity (ADA) and C-reactive protein serum levels (CRP) in chagasic individuals. One hundred and ten individuals, 28 healthy and 82 chagasic patients were divided according to disease severity in phase I (n = 35), II (n = 29), and III (n = 18). A complete medical history, 12-lead electrocardiogram, chest X-ray, and M-mode echocardiogram were performed on each individual. Diagnosis of Chagas disease was confirmed by ELISA and MABA using recombinant antigens; ADA was determined spectrophotometrically and CRP by ELISA. The results have shown that CRP and ADA increased linearly in relation to disease phase, CRP being significantly higher in phase III and ADA at all phases. Also, CRP and ADA were positively correlated with echocardiographic parameters of cardiac remodeling and with electrocardiographic abnormalities, and negatively with ejection fraction. CRP and ADA were higher in patients with cardiothoracic index ≥ 50%, while ADA was higher in patients with ventricular repolarization disturbances. Finally, CRP was positively correlated with ADA. In conclusion, ADA and CRP are prognostic markers of cardiac dysfunction and remodeling in Chagas disease.

scholarly journals Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study

RMD Open ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. e001102 ◽  
Author(s):  
Mette Holland-Fischer ◽  
Reimar W Thomsen ◽  
Ulrik Tarp ◽  
Mette Nørgaard
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Disease Activity ◽  
Population Based ◽  
C Reactive Protein ◽  
Subsequent Infection ◽  
Reactive Protein ◽  
Increased Risk ◽  
First Time

ObjectivePatients with rheumatoid arthritis (RA) experience an increased risk of infections, but the prognosis of infections is unclear. We examined if patients with RA have worse outcomes from pneumonia than non-RA individuals.MethodsIn a population-based cohort study, we computed 90-day mortality rates and crude and adjusted HRs comparing pneumonia patients with and without RA. Among patients with RA, we evaluated prognostic effects of RA medications including prednisolone and disease activity as assessed by C reactive protein (CRP) or platelet levels measured 30–180 days before admission to avoid any influence from the subsequent infection.ResultsAmong 52 577 patients hospitalised for the first time with pneumonia, 1220 (2.3%) had RA. The 90-day mortality was 19.9% for patients with RA and 18.9% for non-RA patients (adjusted 90-day HR of 1.05 (95% CI 0.92 to 1.19)). Compared with CRP levels <8 mg/L, CRP levels ≥20 mg/L predicted increased mortality in patients with RA with adjusted 90-day HRs of 4.98 (95% CI 2.19 to 11.36). Compared with methotrexate monotherapy, both prednisolone (HR 1.43 (95% CI 0.91 to 2.22)) and no RA therapy (HR 1.35 (95% CI 0.85 to 2.14)) tended to increase 90-day mortality. Compared with patients who used prednisolone and had low CRP levels, high CRP predicted increased mortality both in patients who used prednisolone (HR 3.09, 95% CI 1.25 to 7.65) and those who did not (HR 2.35, 95% CI 0.94 to 5.87).ConclusionsOverall, RA does not increase mortality following hospitalisation for pneumonia. However, high RA disease activity prior to admission predicts increased pneumonia mortality in patients regardless of prednisolone use.

Sign in / Sign up

Export Citation Format

Share Document